ACT's eNewsletter, Lab Views, brings you news specific to the laboratory and its uses in clinical trials including deals, alliances, business developments, people news, and events.
FDA Advisory Committee on Cardiovascular Safety
The FDA Endocrinology and Metabolic Drugs Advisory Committee recently voted to recommend that the FDA require pharma companies to establish cardiovascular safety evidence for new diabetes medicines. How will this impact the clinical trials industry? Joel Morganroth, MD, Chief Scientist at eResearch Technology, told Applied Clinical Trials that in the area of cardiovascular testing, "A core ECG laboratory can provide consistent and accurate evaluation of changes from baseline in 12-lead ECG morphology (such as new myocardial infarction pattern) plus identification of interval changes (e.g. QT prolongation and risk for sudden death from an arrhythmia) signals of which may be lost or be falsely positive using site interpreted ECGs. Site interpreted ECG data has so much variability and inaccuracies that core laboratory analysis, like other critical research endpoints, should always be employed."
»MORE
WorldCare Clinical
Providing imaging clinical trial services with the industry’s most efficient technology platform and leading operational and therapeutic expertise.
-
Enterprise-Wide LIMS for Pharma/Biotech Manufacturing
August 4, 2008
The Westin Hotel|Philadelphia, PA
5th Annual Congress: Partnering with Central Labs, Cardiology and Imaging Labs Europe
September 10-11, 2008
Courtyard Marriott Brussels|Belgium
2nd Annual Kinase Inhibitors
October 21-22, 2008
World Trade Center|Boston, MA
Maureen Loftus
- IBT Laboratories' new president and COO.
Yi Zhu
- ACR Image Metrix adds clinical research project manager.
Patrice Hugo, PhD
- MDS Pharma Services' Vice President of Scientific Affairs for its global central labs network.
Sally Warner, Medical Director, Medical Imaging Group for Perceptive Informatics, discusses "The Role of Labs in Imaging Components for Diabetes Trials" in our podcast series titled Challenges & Solutions in Diabetes. Click here to listen.
Parexel has expanded global clinical logistics for centralized coordination of clinical study supplies, lab services, and more.
Cordium Links' joint venture brings central and core lab services to China.
You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.
To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
2 Commerce Drive
Cranbury, NJ 08512